Reporter brief
Nicotinamide Riboside to Improve Functioning in PAD
What happened
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract presents only the study protocol, not results; no efficacy or safety conclusions can be drawn.
- Without reported effect sizes or p-values, the magnitude or statistical significance of any treatment differences cannot be assessed.
- Secondary outcomes including muscle perfusion, oxidative stress, and NAD+ levels are not reported here.
Study design and sample
Rct; Human.
People with peripheral artery disease (PAD) age 50 and older
- Design
- Rct
- Sample
- 250
- Journal
- Northwestern University
- Published
- Aug 24, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Nicotinamide riboside timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.